1
|
Zhang X, Wu H, Tang B, Guo J. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease. Transl Neurodegener 2024; 13:48. [PMID: 39267121 PMCID: PMC11391654 DOI: 10.1186/s40035-024-00437-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Accepted: 08/17/2024] [Indexed: 09/14/2024] Open
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease. The development of PD is closely linked to genetic and environmental factors, with GBA1 variants being the most common genetic risk. Mutations in the GBA1 gene lead to reduced activity of the coded enzyme, glucocerebrosidase, which mediates the development of PD by affecting lipid metabolism (especially sphingolipids), lysosomal autophagy, endoplasmic reticulum, as well as mitochondrial and other cellular functions. Clinically, PD with GBA1 mutations (GBA1-PD) is characterized by particular features regarding the progression of symptom severity. On the therapeutic side, the discovery of the relationship between GBA1 variants and PD offers an opportunity for targeted therapeutic interventions. In this review, we explore the genotypic and phenotypic correlations, etiologic mechanisms, biomarkers, and therapeutic approaches of GBA1-PD and summarize the current state of research and its challenges.
Collapse
Affiliation(s)
- Xuxiang Zhang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Heng Wu
- Department of Neurology, Multi-Omics Research Center for Brain Disorders, The First Affiliated Hospital, University of South China, Hengyang, 421001, China
- Clinical Research Center for Immune-Related Encephalopathy of Hunan Province, Hengyang, 421001, China
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China
- Department of Neurology, Multi-Omics Research Center for Brain Disorders, The First Affiliated Hospital, University of South China, Hengyang, 421001, China
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, 410008, China
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, 410008, China
- Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, 410008, China
- Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, 410008, China
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
| | - Jifeng Guo
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, 410008, China.
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, 410008, China.
- Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, 410008, China.
- Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, 410008, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.
| |
Collapse
|
2
|
Oftedal L, Lange J, Pedersen KF, Erga AH, Dalen I, Tysnes OB, Alves G, Maple-Grødem J. Early GCase activity is a predictor of long-term cognitive decline in Parkinson's disease. Transl Neurodegener 2023; 12:41. [PMID: 37635244 PMCID: PMC10463992 DOI: 10.1186/s40035-023-00373-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 07/27/2023] [Indexed: 08/29/2023] Open
Affiliation(s)
- Linn Oftedal
- Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011, Stavanger, Norway
| | - Johannes Lange
- Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011, Stavanger, Norway
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021, Stavanger, Norway
| | - Kenn Freddy Pedersen
- Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011, Stavanger, Norway
- Department of Neurology, Stavanger University Hospital, 4011, Stavanger, Norway
| | - Aleksander Hagen Erga
- Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011, Stavanger, Norway
- Department of Social Studies, University of Stavanger, 4021, Stavanger, Norway
| | - Ingvild Dalen
- Section of Biostatistics, Department of Research, Stavanger University Hospital, 4011, Stavanger, Norway
| | - Ole-Bjørn Tysnes
- Department of Clinical Medicine, University of Bergen, 5021, Bergen, Norway
- Department of Neurology, Haukeland University Hospital, 5053, Bergen, Norway
| | - Guido Alves
- Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011, Stavanger, Norway
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021, Stavanger, Norway
- Department of Neurology, Stavanger University Hospital, 4011, Stavanger, Norway
| | - Jodi Maple-Grødem
- Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011, Stavanger, Norway.
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021, Stavanger, Norway.
| |
Collapse
|
3
|
Marian OC, Teo JD, Lee JY, Song H, Kwok JB, Landin-Romero R, Halliday G, Don AS. Disrupted myelin lipid metabolism differentiates frontotemporal dementia caused by GRN and C9orf72 gene mutations. Acta Neuropathol Commun 2023; 11:52. [PMID: 36967384 PMCID: PMC10041703 DOI: 10.1186/s40478-023-01544-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 03/12/2023] [Indexed: 03/29/2023] Open
Abstract
Heterozygous mutations in the GRN gene and hexanucleotide repeat expansions in C9orf72 are the two most common genetic causes of Frontotemporal Dementia (FTD) with TDP-43 protein inclusions. The triggers for neurodegeneration in FTD with GRN (FTD-GRN) or C9orf72 (FTD-C9orf72) gene abnormalities are unknown, although evidence from mouse and cell culture models suggests that GRN mutations disrupt lysosomal lipid catabolism. To determine how brain lipid metabolism is affected in familial FTD with TDP-43 inclusions, and how this is related to myelin and lysosomal markers, we undertook comprehensive lipidomic analysis, enzyme activity assays, and western blotting on grey and white matter samples from the heavily-affected frontal lobe and less-affected parietal lobe of FTD-GRN cases, FTD-C9orf72 cases, and age-matched neurologically-normal controls. Substantial loss of myelin-enriched sphingolipids (sulfatide, galactosylceramide, sphingomyelin) and myelin proteins was observed in frontal white matter of FTD-GRN cases. A less-pronounced, yet statistically significant, loss of sphingolipids was also observed in FTD-C9orf72. FTD-GRN was distinguished from FTD-C9orf72 and control cases by increased acylcarnitines in frontal grey matter and marked accumulation of cholesterol esters in both frontal and parietal white matter, indicative of myelin break-down. Both FTD-GRN and FTD-C9orf72 cases showed significantly increased lysosomal and phagocytic protein markers, however galactocerebrosidase activity, required for lysosomal catabolism of galactosylceramide and sulfatide, was selectively increased in FTD-GRN. We conclude that both C9orf72 and GRN mutations are associated with disrupted lysosomal homeostasis and white matter lipid loss, but GRN mutations cause a more pronounced disruption to myelin lipid metabolism. Our findings support the hypothesis that hyperactive myelin lipid catabolism is a driver of gliosis and neurodegeneration in FTD-GRN. Since FTD-GRN is associated with white matter hyperintensities by MRI, our data provides important biochemical evidence supporting the use of MRI measures of white matter integrity in the diagnosis and management of FTD.
Collapse
Affiliation(s)
- Oana C Marian
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - Jonathan D Teo
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - Jun Yup Lee
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - Huitong Song
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - John B Kwok
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
- Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - Ramon Landin-Romero
- Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
- School of Health Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - Glenda Halliday
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia
- Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2006, Australia
| | - Anthony S Don
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, 2006, Australia.
- School of Medical Sciences, The University of Sydney, Camperdown, NSW, 2006, Australia.
| |
Collapse
|
4
|
Oftedal L, Maple-Grødem J, Dalen I, Tysnes OB, Pedersen KF, Alves G, Lange J. Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease. Neurology 2023; 100:e388-e395. [PMID: 36253102 PMCID: PMC9897053 DOI: 10.1212/wnl.0000000000201418] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Accepted: 08/31/2022] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Variations in the glucocerebrosidase gene (GBA) are common risk factors for Parkinson disease (PD) and dementia in PD (PDD) and cause a reduction in the activity of the lysosomal enzyme glucocerebrosidase (GCase). It is anticipated that GCase dysfunction might contribute to a more malignant disease course and predict cognitive impairment in PD, although evidence is lacking. We aimed to discover whether CSF GCase activity is altered in newly diagnosed patients with PD and associated with future development of dementia. METHODS Patients with PD were participants of the ongoing population-based longitudinal ParkWest study in Southwestern Norway and were followed prospectively for up to 10 years. CSF was collected at diagnosis, and GBA carrier status was obtained. Control samples were from persons without neurodegenerative disorders. GCase activity was measured using a validated assay. PD dementia diagnosis was set according to the Movement Disorder Society criteria, and parametric accelerated failure time models were applied to analyze the association of GCase activity with dementia-free survival. RESULTS This study enrolled 117 patients with PD (mean age 67.2 years, including 12 GBA non-synonymous variant carriers) and 50 control participants (mean age 64 years). At the time of diagnosis, GCase activity was reduced in patients with PD with (mean ± SD, 0.92 ± 0.40 mU/mg, n = 12) or without GBA variations (1.00 ± 0.37 mU/mg, n = 105) compared with controls (1.20 ± 0.35, n = 50). GCase activity at the time of diagnosis was lower in patients with PD who developed dementia within 10 years (0.85 ± 0.27 mU/mg, n = 41) than in those who did not (1.07 ± 0.40 mU/mg, n = 76, p = 0.001). A 0.1-unit reduction in baseline GCase activity was associated with a faster development of PDD (hazard ratio 1.15, 95% CI 1.03-1.28, p = 0.014). DISCUSSION The association of early CSF GCase activity with long-term progression to PD dementia will have important implications for the design of clinical trials for GCase targeting therapies and patient management. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that reduced CSF GCase activity at the time of PD diagnosis is associated with an increased risk for later development of PDD.
Collapse
Affiliation(s)
- Linn Oftedal
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital
| | - Jodi Maple-Grødem
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital
| | - Ingvild Dalen
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital
| | - Ole-Bjørn Tysnes
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital
| | - Kenn Freddy Pedersen
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital
| | - Guido Alves
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital
| | - Johannes Lange
- From the The Norwegian Centre for Movement Disorders (L.O., J.M.-G., K.F.P., G.A., J.L.), Stavanger University Hospital, Norway; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A., J.L.), University of Stavanger, Norway; Department of Research (I.D.), Section of Biostatistics, Stavanger University Hospital, Norway; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; and Department of Neurology (K.F.P., G.A.), Stavanger University Hospital.
| |
Collapse
|
5
|
Comparative Investigations on Different β-Glucosidase Surrogate Substrates. FERMENTATION-BASEL 2022. [DOI: 10.3390/fermentation8020083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
β-glucosidases are hydrolyzing enzymes which can release many aroma-active compounds from their glycoside form. Several yeasts produce these enzymes and thus are applied during the wine production process. To be able to test specific organisms for the presence of β-glucosidases and to investigate this enzyme activity, four main surrogate substrates have been described. The properties and applicability of these compounds, named arbutin (hydroquinone-β-D-glucopyranoside), esculin (6-O-(-D-glucosyl)aesculetin), 4-nitrophenyl-β-D-glucopyranoside (pNPG) and 4-methylumbelliferyl-β-D-glucopyranoside (4-MUG), are discussed after comparing their advantages and disadvantages. Although all four substrates were found suitable for photometric assays, 4-MUG has proven to be most appropriate due to high sensitivity, high robustness and simple processing. Furthermore, the investigation of β-glucosidase product accumulation is described, which could be used to give indications about β-glucosidase localization.
Collapse
|
6
|
Ysselstein D, Young TJ, Nguyen M, Padmanabhan S, Hirst WD, Dzamko N, Krainc D. Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity. Mov Disord 2021; 36:2719-2730. [PMID: 34613624 PMCID: PMC8853444 DOI: 10.1002/mds.28815] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 07/24/2021] [Accepted: 09/11/2021] [Indexed: 02/06/2023] Open
Abstract
Mutations in GBA1, which encode for the protein glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's disease and dementia with Lewy bodies. In addition, growing evidence now suggests that the loss of GCase activity is also involved in onset of all forms of Parkinson's disease, dementia with Lewy bodies, and other dementias, such as progranulin-linked frontal temporal dementia. As a result, there is significant interest in developing GCase-targeted therapies that have the potential to stop or slow progression of these diseases. Despite this interest in GCase as a therapeutic target, there is significant inconsistency in the methodology for measuring GCase enzymatic activity in disease-modeling systems and patient populations, which could hinder progress in developing GCase therapies. In this review, we discuss the different strategies that have been developed to assess GCase activity and highlight the specific strengths and weaknesses of these approaches as well as the gaps that remain. We also discuss the current and potential role of these different methodologies in preclinical and clinical development of GCase-targeted therapies. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
| | - Tiffany J. Young
- Ken and Ruth Davee Department of NeurologyNorthwestern University Feinberg School of MedicineChicagoIllinoisUSA
| | | | | | - Warren D. Hirst
- Neurodegenerative Diseases Research UnitBiogenCambridgeMassachusettsUSA
| | - Nicolas Dzamko
- Brain and Mind Centre and Faculty of Medicine and Health, School of Medical SciencesUniversity of SydneyCamperdownNew South WalesAustralia
| | - Dimitri Krainc
- Ken and Ruth Davee Department of NeurologyNorthwestern University Feinberg School of MedicineChicagoIllinoisUSA
| |
Collapse
|
7
|
Omar NAS, Fen YW, Ramli I, Sadrolhosseini AR, Abdullah J, Yusof NA, Kamil YM, Mahdi MA. An Optical Sensor for Dengue Envelope Proteins Using Polyamidoamine Dendrimer Biopolymer-Based Nanocomposite Thin Film: Enhanced Sensitivity, Selectivity, and Recovery Studies. Polymers (Basel) 2021; 13:762. [PMID: 33671059 PMCID: PMC7957696 DOI: 10.3390/polym13050762] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 02/18/2021] [Accepted: 02/20/2021] [Indexed: 11/16/2022] Open
Abstract
This paper proposes a novel idea to enhance the sensitivity and selectivity of surface plasmon resonance (SPR) optical sensor for detection of dengue virus type-2 envelope proteins (DENV-2 E-proteins) using polyamidoamine (PAMAM) dendrimer biopolymer-based nanocomposite thin film. For this purpose, two ranges of DENV-2 E-protein concentrations, i.e., 0.000008-0.0001 nM and 0.00008-0.005 nM were evaluated, and the lowest detectable concentration was achieved at 0.00008 nM. The incorporation of PAMAM dendrimer-based nanocomposite thin film with an SPR sensor exhibited a significant increase in sensitivity and binding affinity to a lower range DENV-2 E-protein concentrations. Moreover, the proposed sensor displayed good selectivity towards DENV-2 E-proteins and have an average recovery of 80-120%. The findings of this study demonstrated that PAMAM dendrimer-based nanocomposite thin film combined with SPR sensor is a promising diagnostic tool for sensitive and selective detection of DENV-2 E-proteins.
Collapse
Affiliation(s)
- Nur Alia Sheh Omar
- Faculty of Science, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia; (N.A.S.O.); (I.R.); (J.A.); (N.A.Y.)
- Institute of Advanced Technology, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia;
| | - Yap Wing Fen
- Faculty of Science, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia; (N.A.S.O.); (I.R.); (J.A.); (N.A.Y.)
- Institute of Advanced Technology, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia;
| | - Irmawati Ramli
- Faculty of Science, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia; (N.A.S.O.); (I.R.); (J.A.); (N.A.Y.)
| | - Amir Reza Sadrolhosseini
- Institute of Advanced Technology, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia;
| | - Jaafar Abdullah
- Faculty of Science, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia; (N.A.S.O.); (I.R.); (J.A.); (N.A.Y.)
| | - Nor Azah Yusof
- Faculty of Science, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia; (N.A.S.O.); (I.R.); (J.A.); (N.A.Y.)
- Institute of Advanced Technology, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia;
| | - Yasmin Mustapha Kamil
- inLAZER Dynamics Sdn Bhd, InnoHub Unit, Putra Science Park, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia;
| | - Mohd Adzir Mahdi
- Wireless and Photonics Network Research Centre, Faculty of Engineering, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia;
| |
Collapse
|